Media about us

• With $40M in New Cash, Epic Sciences Advances Diagnostic for Late-Stage Prostate Cancer

  02 May 2017 Bruce V. Bigelow / Xconomy

  

  When San Diego’s Epic Sciences raised $30 million almost three years ago, CEO Murali Prahalad told me he saw a big opportunity to use the company’s technology as a diagnostic test to assess how well a cancer patient is responding to specific anti-cancer drug regimens.

• Corneal inlays need your boost to hit their stride

  10 April 2017 John A. Hovanesian, MD, FACS / Healio

  

  Recently, ReVision Optics announced the implantation of the 1,000th Raindrop corneal inlay in the United States since its approval last August. The AcuFocus Kamra corneal inlay, which was approved earlier, has now reached nearly 4,000 U.S. implants, according to a source at the company.

• New help for that bane of middle-age: blurry close-up vision

  07 March 2017 Lauran Neergaad, AP Medical Writer / Associated Press

  

  Squinting while texting? Always losing your reading glasses? An eye implant that takes about 10 minutes to put in place is the newest in a list of surgical repairs for the blurry close-up vision that is a bane of middle age. But who's really a good candidate to toss their specs?

• Atlas to invest in extra capacity at STI test manufacturing partner Bespak

  16 February 2017 Dani Bancroft / InPharma Technologist.com

  

  Atlas Genetics has said it will expand manufacturing capacity for cartridgebased STI tests at a UK facility owned by drug delivery technology firm Bespak Europe ltd.

• Liquid biopsies: The next frontier in cancer?

  15 February 2017 Ned Pagliarulo / BioPharmaDive

  

  As immuno-oncology dazzles and pharma companies race to develop new cancer medicines, a similar boom is underway to speed up and improve the detection of cancers.

• Top 5 Vendors in the Pharmerging Market from 2017 to 2021: Technavio

  01 February 2017 Yahoo Finance

  

  The pharmaceutical industry worldwide witnesses a dramatic regional shift to the pharmerging market, owing to the opportunities available. Considering the on-going trend of shift in global medicine dosage consumption to developing countries, about 55-60% of the global consumption should come from pharmerging markets by 2021. This will eventually lead to an incremental growth of around 25% from 2016 level.

• Struggling Marinus gets a bump out of a positive PhII snapshot

  24 January 2017 Arsalan Arif / Endpoints News

  

  A lit­tle more than six months since its stock price was crushed by a failed late-stage pro­gram for its lead­ing — and only — drug, tiny biotech mi­cro­cap Mar­i­nus $MRNS saw its shares shoot up this morn­ing after it of­fered a pos­i­tive Phase II snap­shot on a hand­ful of pa­tients who suf­fer from a rare ge­netic ail­ment.

• Marinus gets a lifeline with new ganaxolone data

  24 January 2017 Ben Adams / Fierce Biotech

  

  Micro cap Marinus Pharmaceuticals was up 28% premarket this morning on positive, early data from its midstage test of ganaxolone in a rare condition that causes severe seizures.

• JP Morgan Healthcare Conference, Day One: Genomic Health, Meridian Bioscience, Qiagen

  11 January 2017 Ed Winnick / GenomeWeb

  

  The 35th Annual JP Morgan Healthcare Conference began here Monday with several life science research tools and diagnostic firms making presentations to investors and other attendees.

• Epic uncovers prostate cancer biomarker

  09 January 2017 Lori Lesko / DDNEWS Cancer Research News

  

  Biotech company Epic Sciences’ focus on circulating tumor cells (CTCs) will not only advance the clinical use of liquid biopsies and improve how metastatic cancer is treated, it says, but also identified a unique CTC biomarker in patients with metastatic prostate cancer who respond to PARP inhibitors cancer drugs in development.